Ithri Benamara is CEO Associate at phagos, a biotech startup developing AI-powered phage therapy. He previously worked as a VC at EQT Ventures, one of Europe's leading investment firms, where he focused on identifying and backing transformative technology companies. Prior to EQT, Ithri also contributed to scaling carbon removal technologies with ClimeFi. He holds Master's degrees in Climate Change & Sustainable Finance from Ecole des Mines de Paris and EDHEC Business School.
Se prevé que la resistencia a los antimicrobianos causará 10 millones de muertes al año para 2050. La terapia con bacteriófagos podría ayudar a contrarrestar ese problema.
Antimicrobial resistance is set to cause 10 million annual deaths by 2050. Bacteriophage therapy can help fill the void left by a lack of new antibiotics.
